Susan M Wood

US Patent:

6671819, Dec 30, 2003

Filed:

Apr 6, 2000

Appl. No.:

09/544824

Inventors:

William S. Passman - Lexington MA
John R. Zavgren - Acton MA
Susan L. Wood - Wolcott VT
Keith W. Manning - Arlington MA
Joseph J. Weinstein - Somerville MA

Assignee:

BBNT Solutions LLC - Cambridge MA

International Classification:

H04L 1256

US Classification:

714 4, 370400

Abstract:

A network for routing packets includes multiple nodes. A first node has a direct link to a second node. The first node receives a packet and identifies a primary next hop to which to transmit the packet ( ). The primary next hop identifies at least the second node. The first node transmits the packet to the second node ( ), determines whether the transmission was successful ( ), and identifies at least a third node when the transmission to the second node was unsuccessful. The first node identifies the third node by: finding a node in the network that has a direct link to both the first and second nodes ( ); identifying at least one alternate next hop, assuming that the link between the first and second nodes is unavailable, determining the cost associated with each of the alternate next hops, and selecting one of the alternate next hops based on the determined cost ( ); or retrieving a predetermined alternate next hop from a forwarding table stored by the first node ( ). The first node then transmits the packet to the third node for forwarding to the second node ( ).

US Patent:

20130288966, Oct 31, 2013

Filed:

Nov 19, 2012

Appl. No.:

13/680381

Inventors:

Melissa M. Haskell - Uxbridge MA, US
Denis Schrier - Hopkinton MA, US
Susan A. Wood - Dedham MA, US

International Classification:

A61K 38/18

US Classification:

514 88, 514 89

Abstract:

The present invention is directed to methods and compositions for accomplishing systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-β superfamily via a peripheral mode of administration. According to the invention, an exemplary bioactive agent is BMP-7. The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the peripheral site of intravenous administration of the bioactive agent.

US Patent:

20180369413, Dec 27, 2018

Filed:

Jun 19, 2018

Appl. No.:

16/012138

Inventors:

- Lexington MA, US
Frank DeRosa - Lexington MA, US
Jonathan Cherry - Lexington MA, US
Paula Lewis - Lexington MA, US
Shrirang Karve - Lexington MA, US
Zarna Patel - Lexington MA, US
Darshan Parekh - Lexington MA, US
Susan Wood - Lexington MA, US
Chi-Sung Chiu - Lexington MA, US
Caroline J. Woo - Lexington MA, US

International Classification:

A61K 48/00
C12N 15/62
A61K 38/02
C12N 15/52
A61K 38/17
A61P 21/00
A61K 9/127

Abstract:

The present invention provides methods and compositions of treating Friedreich's ataxia (FRDA) based on administering an mRNA encoding a frataxin protein.

US Patent:

20140336595, Nov 13, 2014

Filed:

Feb 21, 2014

Appl. No.:

14/186545

Inventors:

- Kalamazoo MI, US
Melissa M. Haskell - Uxbridge MA, US
Denis Schrier - Hopkinton MA, US
Susan A. Wood - Dedham MA, US

Assignee:

STRYKER CORPORATION - Kalamazoo MI

International Classification:

A61M 5/00
A61K 9/00
A61K 38/18

US Classification:

604272, 514 88, 514 89

Abstract:

The present invention is directed to methods and compositions for accomplishing systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-β superfamily via a peripheral mode of administration. According to the invention, an exemplary bioactive agent is BMP-7. The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the peripheral site of intravenous administration of the bioactive agent.

US Patent:

20140187486, Jul 3, 2014

Filed:

Jul 18, 2013

Appl. No.:

13/945317

Inventors:

- Kalamazoo MI, US
Melissa M. Haskell - Uxbridge MA, US
Denis Schrier - Hopkinton MA, US
Susan A. Wood - Dedham MA, US

Assignee:

Stryker Corporation - Kalamazoo MI

International Classification:

A61K 38/18
A61M 5/00
A61K 9/00

US Classification:

514 88, 514 89, 604272

Abstract:

The present invention is directed to methods and compositions for accomplishing systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-β superfamily via a peripheral mode of administration. According to the invention, an exemplary bioactive agent is BMP-7. The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the peripheral site of intravenous administration of the bioactive agent.